Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trubion Pharmaceuticals Inc.

Division of Emergent BioSolutions Inc.

Latest From Trubion Pharmaceuticals Inc.

Nordic's $62m IPO reheats anti-CD37 cancer therapies

In the biggest life science initial public offering on a European exchange since November 2014, Nordic Nanovector grossed NOK 500m ($62.3m) from its IPO on the Oslo stock exchange on 23 March 2015. The company raised 20% more than it had originally planned, allowing it now to reach comfortably beyond the first regulatory submission for its lead product Betalutin (177Lu-tetulomab) in non-Hodgkin's lymphoma (NHL). The IPO also potentially breathes new life into an old blood cancer target, CD37.

Cancer Companies

ASH 2013: Emergent's otlertuzumab maintains ORR lead in Phase II

Updated Phase II results for otlertuzumab from Emergent BioSolutions plus Teva Pharmaceutical's Treanda (bendamustine), which were presented at the American Society of Hematologists (ASH) Annual Meeting on 8 December, show that the CD37-targeting monoclonal antibody is maintaining its lead over Treanda alone.

Cardiovascular Cancer

ASH data to watch: GlycoMimetics, Ambit, Emergent

Stock prices for Ambit Biosciences and Emergent BioSolutions dipped after abstracts for their data presentations at the upcoming American Society of Hematologists (ASH) Annual Meeting and Exposition became public on 7 November, and GlycoMimetics postponed its initial public offering on 8 November, but all three companies have data worth watching when ASH welcomes doctors and scientists to New Orleans from 7 to 10 December.

Cardiovascular Infectious Diseases

Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule

Though Abraxane (paclitaxel) is now part of Celgene Corp.'s growing oncology portfolio, you don't need Celgene stock to invest in its newest product, a reformulation of the generic chemotherapy that's approved to treat metastatic breast cancer. As part of Celgene's cash-and-stock $2.9 billion acquisition of Abraxis BioScience Inc. Celgene deferred at least $650 million in potential payments to Abraxis shareholders, plus royalty payments tied to Abraxane sales. Unlike most earn-out-laden deals, however, the contingency value rights, or CVRs, for the earn-outs have been securitized and now trade under the ticker CELGZ. Despite potential advantages - tradeable CVRs let shareholders bet on the success or failure of specific assets, for instance - these investment vehicles are still a rarity in the marketplace.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • GeneCraft Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Emergent BioSolutions Inc.
  • Senior Management
  • Steven Gillis, PhD, Chmn. & Acting CEO
    John Bencich, VP, CFO
    Kendall Mohler, PhD, SVP, CSO
  • Contact Info
  • Trubion Pharmaceuticals Inc.
    Phone: (206) 838-0500
    2401 Fourth Ave.
    Ste. 1050
    Seattle, WA 98121